论文期刊

取消

高级检索

检索历史清除

首页> Expert review of pharmacoeconomics & outcomes research> Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.

Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.

导出 LinkOut

翻译打印收藏纠错

作者： Cheng Ean,Chee ^[1] ; Jasmeet Singh,Khara ^[2] ; John,Cheong ^[3] ; Jek,Fong ^[3] ; Sivabalan,Sivanesan ^[2] ; Jian Yi,Choy ^[4] ; Meibo,Hu ^[4] ; Amrita,Viswambaram ^[4] ; Han Chong,Toh ^[5]

作者单位： Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore. ^[1] Medical, Roche Singapore Pte Ltd, Singapore, Singapore. ^[2] Market Access, Roche Singapore Pte Ltd, Singapore, Singapore. ^[3] Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore. ^[4] Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. ^[5]

关键词 Atezolizumab bevacizumab cost-effectiveness hepatocellular carcinoma programmed death ligand-1 sorafenib

主题词人类(Humans);费用效益分析(Cost-Benefit Analysis);新加坡(Singapore);肝肿瘤(Liver Neoplasms);癌, 肝细胞(Carcinoma, Hepatocellular);质量校正寿命(Quality-Adjusted Life Years);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);药费支出(Drug Costs)

DOI 10.1080/14737167.2024.2319607

PMID 38776431

发布时间 2024-05-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Expert review of pharmacoeconomics & outcomes research

Expert review of pharmacoeconomics & outcomes research

2024年24卷5期

631-641页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Expert review of pharmacoeconomics & outcomes research

点击下载本期目录封面

Expert review of pharmacoeconomics & outcomes research

2024年24卷5期

631-641页

相关期刊

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷